ImmuCell Corp. (ICCC)
9.75
+0.15
(+1.56%)
USD |
NASDAQ |
Oct 02, 16:00
ImmuCell Gross Profit Margin (Quarterly) : 33.92% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 33.92% |
| March 31, 2026 | 44.97% |
| December 31, 2025 | 38.16% |
| September 30, 2025 | 42.92% |
| June 30, 2025 | 43.72% |
| March 31, 2025 | 41.58% |
| December 31, 2024 | 36.54% |
| September 30, 2024 | 26.34% |
| June 30, 2024 | 22.48% |
| March 31, 2024 | 31.63% |
| December 31, 2023 | 24.69% |
| September 30, 2023 | 23.48% |
| June 30, 2023 | 29.55% |
| March 31, 2023 | 8.73% |
| December 31, 2022 | 15.83% |
| September 30, 2022 | 29.15% |
| June 30, 2022 | 44.21% |
| March 31, 2022 | 51.72% |
| December 31, 2021 | 47.04% |
| September 30, 2021 | 46.96% |
| June 30, 2021 | 45.67% |
| March 31, 2021 | 39.01% |
| December 31, 2020 | 43.31% |
| September 30, 2020 | 46.27% |
| June 30, 2020 | 43.26% |
| Date | Value |
|---|---|
| March 31, 2020 | 45.54% |
| December 31, 2019 | 36.73% |
| September 30, 2019 | 32.87% |
| June 30, 2019 | 28.48% |
| March 31, 2019 | 41.05% |
| December 31, 2018 | 47.53% |
| September 30, 2018 | 44.15% |
| June 30, 2018 | 49.32% |
| March 31, 2018 | 47.19% |
| December 31, 2017 | 38.68% |
| September 30, 2017 | 46.68% |
| June 30, 2017 | 52.66% |
| March 31, 2017 | 60.72% |
| December 31, 2016 | 55.06% |
| September 30, 2016 | 61.21% |
| June 30, 2016 | 52.19% |
| March 31, 2016 | 58.85% |
| December 31, 2015 | 61.51% |
| September 30, 2015 | 65.20% |
| June 30, 2015 | 57.67% |
| March 31, 2015 | 59.68% |
| December 31, 2014 | 60.91% |
| September 30, 2014 | 60.89% |
| June 30, 2014 | 57.06% |
| March 31, 2014 | 55.24% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 90.81% |
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Savara, Inc. | -- |
| Vericel Corp. | 72.82% |
| Biogen, Inc. | 61.37% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 2.67% |
| Return on Assets | 1.74% |
| Return on Invested Capital | 1.84% |
| Profit Margin (Quarterly) | 25.53% |
| Operating Margin (Quarterly) | -0.91% |
| Return on Net Operating Assets | 2.01% |